



IBA – TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, January 29, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on January 26 and 29, 2018.

Reason for the notification	Upwards crossing followed by a downwards crossing of the 3% threshold further to the acquisition and disposal of shares –and thus voting rights- held as loan collateral	
Persons subject to the notification requirement	IBA SA, issuer	
Persons that dispose of voting rights	Norges Bank	
Transaction date	24/01/2018	25/01/2018
Threshold that is crossed (in %)	3% Upwards crossing further to the acquisition of voting rights	3% Downwards crossing further to the disposal of voting rights
Denominator	29 962 246	29 962 246
Voting rights (number)	899 685	859 382
Voting rights (%)	3,00%	2,87%
Chain of control	Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway's foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.	
Additional information	This notification was triggered as a result of a change in collateral.	

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle

Press Release

Regulated information



accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Stephanie Bauwin

Legal Counsel

+32 10 203 924

Stephanie.bauwin@iba-group.com